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doi:10.1016/j.gmbhs.2012.04.008Abstract Human uterine cancer occurs most often in menopause women between the ages of
55 and 70 years. In the initial stage, the symptoms of uterus have an abnormal vaginal bleeding
or abnormal discharge, and the common treatment is to remove the uterus or treat with
chemotherapeutic drugs. For most type of cancers, doxorubicin is frequently prescribed for
treating a wide range of various types of cancers, including hematologic malignancies,
lymphoma, myeloma, sarcoma, and uterine cancer. However, most cancer cells will become
drug insensitivity or resistance via unknown mechanisms. Since mitochondria play a crucial role
in the induction apoptosis, it is intriguing to clarify whether doxorubicin-resistance is mediated
through mitochondrial protection. In this study, a highly doxorubicin-resistant cell line has
been established by continuously culturing the MES-SA/Dx5, a commercial doxorubicin-
resistant human uterine cancer cell line, in the presence of doxorubicin for up to 2 years. Mito-
chondrial proteins from nondrug-resistant MES-SA, low resistant MES-SA/Dx5 (MES-SA/Dx5low),
and high resistant MES-SA/Dx5 (MES-SA/Dx5high) were enriched, and mitochondrial proteome is
characterized by two dimensional-differential gel electrophoresis and matrix-assisted laser
desorption/ ionization time of flight mass spectrometer (MALDI-TOF MS).
Copyright ª 2012, Taiwan Genomic Medicine and Biomarker Society. Published by Elsevier
Taiwan LLC. All rights reserved.of Applied Science, National
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an Genomic Medicine and BiomaIntroduction
Uterine cancer is one of the ten leading causes of death of
cancer and the most commonly diagnosed gynecologic
cancer. The most common type of uterine cancer is called
endometrial cancer because it forms in the lining of uterus
called the endometrium. Most endometrial cancers arerker Society. Published by Elsevier Taiwan LLC. All rights reserved.
Figure 2 Western blot analysis of Tubulin-beta and COX IV in
cytosolic and mitochondrial fractions of uterine cancer cells.
58 Y.-W. Lo et al.adenocarcinomas. Endometrial cancer is often diagnosed
using an endometrial biopsy or dilation and curettage (D&C)
when a woman presents with symptoms. Medicines, such as
doxorubicin used alone or in combination with cisplatin,
paclitaxel, and so on, may be given after surgery for
endometrial cancer depending on the stage of the
cancer and the risk for the cancer to spread or recur.
However, chemotherapeutic uterine cancer is a major
impediment to cancer therapy because long-term drug use
can affect drug efficacy through changes in cell cycle,
apoptosis pathway, metabolism, DNA repair, and drug
efflux.1 Mitochondria play important roles in cellular energy
metabolism, free-radical generation, and apoptosis.
Defects in mitochondrial function have been proposed to
contribute todrug-resistance pathway activation.2,3,4,5
Herein, we tested the hypothesis that mitochondrial
alteration and their led to drug-resistance.
Materials and methods
Cell line and culture
Cell lines used in this study are MES-SA, MES-SA/Dx5low and
MES-SA/ Dx5high. Human uterine sarcoma cell line MES-SA
and its doxorubicin selected drug resistant cell line MES-SA/
Dx5low are purchased from ATCC (Washington, DC, USA).5
MES-SA/ Dx5high, derived from MES-SA/Dx5low, is a multi-
drug resistant (MDR) variant that possess both self-renewal
capabilities and the expression of p-glycoprotein (MDR-1)
by constitutively selection with doxorubicin (data not
shown). MES-SA/Dx5low and MES-SA/Dx5high were cultured
in McCoy’ 5A with 1.5 g/L sodium bicarbonate containing
10% (v/v) fetal bovine serum and 1 IU/mL penicillin/
streptomycin at 37 C and 5% CO2.
Sample preparation
Firstly, 5  107 of MES-SA, MES-SA/Dx5low and MES-SA/
Dx5high cells were collected and washed with ice-cold
buffer solution phosphate buffered saline (PBS).
Mitochondria-enriched fractions are isolated using the
mitochondria/cytosol fractionation kit (Millipore, MA, USA),
1 ml of 1  cytosol extraction buffer containing redoxFigure 1 Effect of doxorubicin on the viability of uterine
cancer cells.reagent dithiothreitol (DTT) and protease inhibitors on ice
for 10 minutes. Later, cells were homogenized in an ice-
cold of tissue grinder, and then centrifuged at 700 g for
10 minutes at 4 C. The supernatant was centrifuged at
10,000 g for 30 minutes at 4 C. The cell pellet was
mitochondrial-enriched fraction.6
Doxorubicin dose response curve
Uterine sarcoma cells were seeded in 96-well plates and
treated with various concentrations of doxorubicin for
24 hours. MTT cell viability assay was performed to measure
the activity of mitochondrial succinate dehydrogenase that
reduce MTT [3- (4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetra-
zolium bromide] to formazan dyes. After removal of the
medium,50ml ofMTTworking solutionwasadded to thecells in
each well followed by incubation at 37 C for 4 hours. The
supernatant was carefully removed. One hundred microliters
of dimethyl sulfoxide (DMSO) was added to each well and the
plates were shaken for 20 minutes. The absorbance of the
samples was then measured at a wavelength of 540 nm in
a multiwell-plate reader.
Two dimensional-differential gel
electrophoresisanalysis
Before performing two dimensional-differential gel elec-
trophoresis (2D-DIGE), the samples were labeled with theFigure 3 Representative 2D-DIGE image showing the sepa-
ration of mitochondrial proteins of uterine cancer cells.
Table 1 Protein identification of differentially expressed mitochondrial proteins between doxorubicin-sensitive and
doxorubicin-resistant cells.
Spot number Protein
name
isoelectric point (pI) Molecular
weight
Number of
matched
peptides
Coverage (%) Score Matched peptides
434 1 4.29 48283 8/20 17 79/56 EQFLDGDGWTSR
482 2 7.96 58470 5/9 15 72/56 NTGIICTIGPASR
528 3 6.3 55454 5/14 10 61/56 QAFQIGSPWR
593 4 5.06 53676 8/24 18 62/56 TYSLGSALRPSTSR
628 5 7.71 56251 6/17 58 58/56 LLWNWWK
653 6 6.3 55454 9/24 19 82/56 QAFQIGSPWR
661 7 5.06 53676 7/40 15 63/56 SYVTTSTR
666 8 6.07 6756 4/19 20 66/56 MQCQLFR
667 9 6.02 78265 6/22 10 57/56 QQISGIQPHGLPNALDDR
669 10 5.43 35806 5/25 15 61/56 APLDLDKYVEIAR
671 11 5.75 161030 8/19 4 61/56 EQIEHHPR
680 12 5.84 46161 4/10 12 60/56 HEFPFR
681 13 5.84 46161 4/13 12 58/56 MGGEAGCAAAVGAEGR
691 14 6.1 10544 5/20 44 68/66 EVGQLAETQR
706 15 4.87 74959 7/26 14 56/56 VYGAQNEMCLATQQLSK
717 16 6.3 55454 11/23 23 81/56 QAFQIGSPWR
748 17 6.3 55454 9/24 17 76/56 QAFQIGSPWR
748 18 6.3 55454 10/19 20 105/56 QAFQIGSPWR
774 19 5.26 56525 5/12 12 64/56 LVLEVAQHLGESTVR
785 20 6.56 104912 10/26 10 56/56 EEIVKAGLK
804 21 6.56 104912 10/31 11 57/56 KLAQALLEQGGR
818 22 7.01 47481 8/23 20 89/56 AAVPSGASTGIYEALELR
829 23 7.01 47481 10/36 20 83/56 AAVPSGASTGIYEALELR
829 24 5.99 42199 5/25 15 57/56 VYADGIFDLFHSGHAR
840 25 5.59 223946 15/31 8 58/56 IHFGTTGK
981 26 8.3 44985 6/21 16 68/56 NNQITNNQR
1138 27 6.28 64887 8/33 15 57/56 YFGAHERLEETK
1160 28 8.91 33863 7/31 25 58/56 SWDPNPVPRTLR
1173 29 8.54 65916 6/21 11 58/56 MQWLMR
1339 30 8.56 61634 7/25 15 58/56 MTTSLQDGQSAASRAAAR
1509 31 9.63 17104 5/22 33 58/56 MELVQVLKR
1511 32 9.01 66808 7/40 12 57/56 MGTTGLESLSLGDR
1527 33 4.87 74959 6/17 12 57/56 VYGAQNEMCLATQQLSK
1600 34 5.7 27815 4/15 20 63/56 ELPAAVAPAGPASLAR
1719 35 5.46 95729 7/15 7 59/56 EAEFLQK
1734 36 4.87 74959 6/17 12 64/57 VYGAQNEMCLATQQLSK
1854 37 8.93 83611 6/10 7 60/56 GHVHRLVSGK
1857 38 8.27 22324 8/16 38 92/56 IGHPAPNFK
1858 39 8.27 22324 5/11 18 62/56 ADEGISFR
1882 40 8.16 66149 5/14 12 58/56 SLNNQFASFIDK
1933 41 5.66 22049 5/13 23 56/56 EGGLGPLNIPLLADVTR
2053 42 5.62 74033 6/18 9 56/56 LENLIIK
2058 43 5.43 35806 4/13 10 57/56 MAPLDLDK
2107 44 5.34 15048 6/22 58 69/56 ACGLVASNLNLKPGECLR
Mitochondrial proteins in doxorubicin resistance 59cyanine dyes containing Cy2, Cy3, and Cy5. Briefly, the
protein sample was individual labeled with Cy3 and Cy5.
Separated all samples were labeled with Cy2, which was
an internal standard to all gels. The labeled samples
were incubated in the dark for 30 minutes on ice, and
then the reaction was stopped by the addition of
L-lysine. The Cy3 and Cy5 labeled samples were
combined and mixed with an equal volume with Cy2-labeled internal standard. After the addition of DTT and
carrier ampholyte IPG (immobilized pH gradient) buffer,
the final volume was adjusted to 450 ml with 2D-lysis
buffer. Nonlinear strips (pH3-10, 24 cm) were rehydrated
by CyDye-labeled samples in the dark at room tempera-
ture overnight. 2D-DIGE was performed and gel analysis
was used DeCyder (GE Healthcare, Uppsala, Sweden) to
2D differential analysis.
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The interested proteins on 2D gel were subjected to in-gel
digestion. The peptide samples were dissolved in 0.1% tri-
fluoroacetic acid (TFA), spot on an anchor chip target plate,
cover matrix a- cyano-4-hydroxy-cinnamic acid (HCCA)
after samples become dried. The peptide mass fingerprint
was analyzed by matrix-assisted laser desorption/ ioniza-
tion time of flight mass spectrometer (MALDI-TOF-MS)
(Bruker Daltonics Inc., Bremen, Germany), and Mascot
search software (Matrix Science, London, UK) was used to
identify these proteins.
Results
As shown in Fig. 1, doxorubicin different induced death of
MES-SA and multidrug-resistant cell lines MES-SA/Dx5low and
MES-SA/Dx5high cells. Compared with MES-SA/Dx5low and
MES-SA/Dx5high cells, MES-SA cells were more sensitive to the
cytotoxicity of doxorubicin. Mitochondrial-enriched fractions
were successfully isolated as evidenced by Western blot
analysis of tubulin-beta (cytosolic marker) and cytochrome c
oxidase IV (COX IV) (mitochondrial marker). This is shown in
Fig. 2. The mitochondrial proteomic profiles of MES-SA, MES-
SA/Dx5 low, and MES-SA/Dx5 high were conducted by three
replicates of the different mitochondrial extracts. A repre-
sentative 2D gel is shown in Fig. 3. The results of MALDI-TOF
MS analyses on gel-to-gel variation of spots identified alter-
ations in mitochondrial protein expression in MES-SA, MES-
SA/Dx5low, and MES-SA/Dx5high cells (Table 1). Several
differentially expressed proteins may merit study further
and identify their contribution to doxorubicin-resistant
phenotype.7Discussion
Uterine cancer is notoriously known for its resistant to doxo-
rubicin treatment, but themechanisms responsible for doxo-
rubicin resistance remain to be clarified. Proteomic analysis
on mitochondrial proteins may elucidate their importance in
tumor growth, angiogenesis, metastasis, and cancer progres-
sion. Extensive studies on differentially expressed proteins
may lead to find novel targets for uterine cancer therapy.References
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